Skip to content

Metabolic Determinants of Cardiac Function

Metabolic Determinants of Cardiac Function

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03386864
Enrollment
400
Registered
2017-12-29
Start date
2016-04-30
Completion date
2020-04-30
Last updated
2023-08-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes Mellitus, Heart Failure

Keywords

Heart Failure, Diabetes Mellitus, Mitochondrial Respiration

Brief summary

Assessment of cardiac energy metabolism in patients with impaired glucose tolerance

Detailed description

Insulin resistance, hepatocellular lipids (HCL) and plasma concentrations of free fatty acids (FFA) are predictors of heart failure, the leading cause of mortality in patients suffering from type 2 diabetes mellitus (T2DM). Epidemiological data suggest that diabetic cardiomyopathy (DC) presents as ventricular dysfunction in patients with T2DM independent of coronary artery disease. The underlying cellular mechanisms are poorly understood. Reduced mitochondrial activity and insulin resistance of skeletal muscle relates to liver steatosis, possibly due to higher substrate flux to the liver. High oxidation rates in the liver result in oxidative stress, damage of mitochondria and apoptosis. The investigators hypothesize that (i) HCL and impaired liver energy metabolism correlate with ventricular dysfunction, (ii) impaired glucose uptake and mitochondrial capacity in skeletal muscle relates to enhanced oxidative capacity, oxidative stress and lipid deposition in heart tissue (iii) reduced myocardial oxidative capacity limits recovery of myocardial function in patients with acute heart failure. The investigators aim to assess (i) liver energy metabolism and heart function, (ii) respiration and lipid metabolites in skeletal muscle and heart tissue in humans with advanced heart failure and (iii) the prognostic impact of these factors in humans with acute heart failure. This study will improve the understanding of mechanisms underlying the development of DC and the identification of patients at risk for poor outcome in heart failure.

Interventions

None listed

Sponsors

Heinrich-Heine University, Duesseldorf
CollaboratorOTHER
German Diabetes Center
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
20 Years to 85 Years
Healthy volunteers
No

Inclusion criteria

* age ≥ 20 and ≤85 years * myocardial biopsy for medical reason

Exclusion criteria

* acute infection * autoimmune disease * pregnancy * cancer

Design outcomes

Primary

MeasureTime frameDescription
mitochondrial oxygen fluxUp to 36 monthsmeasured using high resolution respirometry. Unit: pmol/(s\*mg)

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026